330 related articles for article (PubMed ID: 28334439)
21. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
22. Clinical and genomic correlates of imatinib response in melanomas with KIT alterations.
Jung S; Armstrong E; Wei AZ; Ye F; Lee A; Carlino MS; Sullivan RJ; Carvajal RD; Shoushtari AN; Johnson DB
Br J Cancer; 2022 Nov; 127(9):1726-1732. PubMed ID: 35999272
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.
Guo J; Carvajal RD; Dummer R; Hauschild A; Daud A; Bastian BC; Markovic SN; Queirolo P; Arance A; Berking C; Camargo V; Herchenhorn D; Petrella TM; Schadendorf D; Sharfman W; Testori A; Novick S; Hertle S; Nourry C; Chen Q; Hodi FS
Ann Oncol; 2017 Jun; 28(6):1380-1387. PubMed ID: 28327988
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.
Wong SJ; Karrison T; Hayes DN; Kies MS; Cullen KJ; Tanvetyanon T; Argiris A; Takebe N; Lim D; Saba NF; Worden FP; Gilbert J; Lenz HJ; Razak AR; Roberts JD; Vokes EE; Cohen EE
Ann Oncol; 2016 Feb; 27(2):318-23. PubMed ID: 26598548
[TBL] [Abstract][Full Text] [Related]
25. KIT gene mutations and patterns of protein expression in mucosal and acral melanoma.
Abu-Abed S; Pennell N; Petrella T; Wright F; Seth A; Hanna W
J Cutan Med Surg; 2012; 16(2):135-42. PubMed ID: 22513068
[TBL] [Abstract][Full Text] [Related]
26. Characterization of S628N: a novel KIT mutation found in a metastatic melanoma.
Vita M; Tisserand JC; Chauvot de Beauchêne I; Panel N; Tchertanov L; Agopian J; Mescam-Mancini L; Fouet B; Fournier B; Dubreuil P; Bertucci F; De Sepulveda P
JAMA Dermatol; 2014 Dec; 150(12):1345-9. PubMed ID: 25317746
[TBL] [Abstract][Full Text] [Related]
27. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas.
Ashida A; Takata M; Murata H; Kido K; Saida T
Int J Cancer; 2009 Feb; 124(4):862-8. PubMed ID: 19035443
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
29. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
30. Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07).
Montemurro M; Cioffi A; Dômont J; Rutkowski P; Roth AD; von Moos R; Inauen R; Toulmonde M; Burkhard RO; Knuesli C; Bauer S; Cassier P; Schwarb H; Le Cesne A; Koeberle D; Bärtschi D; Dietrich D; Biaggi C; Prior J; Leyvraz S
Cancer; 2018 Apr; 124(7):1449-1454. PubMed ID: 29315500
[TBL] [Abstract][Full Text] [Related]
31. Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway.
Mao L; Dai J; Cao Y; Bai X; Sheng X; Chi Z; Cui C; Kong Y; Zhang Y; Wu L; Wang X; Tang B; Lian B; Yan X; Li S; Zhou L; Wei X; Li C; Qi Z; Si L; Guo J
Eur J Cancer; 2021 May; 148():297-306. PubMed ID: 33770575
[TBL] [Abstract][Full Text] [Related]
32. Sunitinib therapy for melanoma patients with KIT mutations.
Minor DR; Kashani-Sabet M; Garrido M; O'Day SJ; Hamid O; Bastian BC
Clin Cancer Res; 2012 Mar; 18(5):1457-63. PubMed ID: 22261812
[TBL] [Abstract][Full Text] [Related]
33. STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.
Delyon J; Chevret S; Jouary T; Dalac S; Dalle S; Guillot B; Arnault JP; Avril MF; Bedane C; Bens G; Pham-Ledard A; Mansard S; Grange F; Machet L; Meyer N; Legoupil D; Saiag P; Idir Z; Renault V; Deleuze JF; Hindie E; Battistella M; Dumaz N; Mourah S; Lebbe C;
J Invest Dermatol; 2018 Jan; 138(1):58-67. PubMed ID: 28843487
[TBL] [Abstract][Full Text] [Related]
34. A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
Ott PA; Pavlick AC; Johnson DB; Hart LL; Infante JR; Luke JJ; Lutzky J; Rothschild NE; Spitler LE; Cowey CL; Alizadeh AR; Salama AK; He Y; Hawthorne TR; Bagley RG; Zhang J; Turner CD; Hamid O
Cancer; 2019 Apr; 125(7):1113-1123. PubMed ID: 30690710
[TBL] [Abstract][Full Text] [Related]
35. Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma.
Storkus WJ; Maurer D; Lin Y; Ding F; Bose A; Lowe D; Rose A; DeMark M; Karapetyan L; Taylor JL; Chelvanambi M; Fecek RJ; Filderman JN; Looney TJ; Miller L; Linch E; Lowman GM; Kalinski P; Butterfield LH; Tarhini A; Tawbi H; Kirkwood JM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34782430
[TBL] [Abstract][Full Text] [Related]
36. MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.
Zhan Y; Guo J; Yang W; Goncalves C; Rzymski T; Dreas A; Żyłkiewicz E; Mikulski M; Brzózka K; Golas A; Kong Y; Ma M; Huang F; Huor B; Guo Q; da Silva SD; Torres J; Cai Y; Topisirovic I; Su J; Bijian K; Alaoui-Jamali MA; Huang S; Journe F; Ghanem GE; Miller WH; Del Rincón SV
J Clin Invest; 2017 Nov; 127(11):4179-4192. PubMed ID: 29035277
[TBL] [Abstract][Full Text] [Related]
37. Nilotinib in patients with metastatic melanoma harboring KIT gene aberration.
Cho JH; Kim KM; Kwon M; Kim JH; Lee J
Invest New Drugs; 2012 Oct; 30(5):2008-14. PubMed ID: 22068222
[TBL] [Abstract][Full Text] [Related]
38.
Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
[TBL] [Abstract][Full Text] [Related]
39. Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma.
Alexander M; Mellor JD; McArthur G; Kee D
Med J Aust; 2014 Jul; 201(1):49-53. PubMed ID: 24999899
[TBL] [Abstract][Full Text] [Related]
40. Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma.
McKean M; Oba J; Ma J; Roth KG; Wang WL; Macedo MP; Carapeto FCL; Haydu LE; Siroy AE; Vo P; Hong DS; Eterovic AK; Patel KP; Bassett RL; Grimm EA; Lazar AJ; Woodman SE
J Invest Dermatol; 2019 Mar; 139(3):728-731. PubMed ID: 30798855
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]